New Bronchodilator Approved For COPD In Nebulizer

New Bronchodilator – First Of Its Class For Use In Nebulizer

On December 5, 2017, the United States Food and Drug Administration (FDA) announced approval of a new bronchodilator as a long-acting nebulized medication. Lonhala is the brand name of the medication, while the generic name is glycopyrrolate. It is also known as SUN-101/eFlow®. Magnair is the brand name of the eFlow® nebulizer system developed by PARI Pharma GmbH. According to the FDA, Lonhala Magnair is indicated for “long term, twice each day (morning and evening) maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.” Why Is It Unique? It is the first long-acting muscarinic antagonist (LAMA) bronchodilator available in a solution to be used in a nebulizer. The other type of bronchodilator is called a beta-agonist. These two classes of bronchodilators work in different ways to open the breathing tubes (airways). The Magnair nebulizer is a silent and portable delivery device that reduces the amount of time required for someone with COPD to inhale the medication in two to three minutes.
Lonhala Magnair is a muscarinic antagonist bronchodilator solution

Lonhala Magnair is a long-acting bronchodilator delivered by the e-Flow nebulizer

Nebulized medications offer an alternative to metered-dose inhalers, soft mist inhalers, and dry powder inhalers. They allow a person to breathe normally in and out while inhaling the medicine.
Metered-dose inhaler

Metered-dose inhaler

Soft mist inhaler

Soft mist inhaler

My Comments  Lonhala Magnair is the first long-acting muscarinic antagonist bronchodilator available for the nebulized treatment of those with COPD. There are two long- acting nebulized beta-agonist bronchodilators available – Brovana and Perforomist. Both last 12 hours, are used twice daily, and are used with a jet nebulizer. 
Jet nebulizer system

Jet nebulizer system

I expect that this new bronchodilator will be used in addition to Brovana or Perforomist to provide more effective opening of the breathing tubes (bronchodilation) when a nebulizer is used. Please view my financial disclosures under the heading ABOUT.

Donald A. Mahler, M.D. is Emeritus Professor of Medicine at Geisel School of Medicine at Dartmouth in Hanover, New Hampshire. He works as a pulmonary physician at Valley Regional Hospital in Claremont, NH, where he is Director of Respiratory Services.